GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Equity-to-Asset

ARCA biopharma (FRA:HQ10) Equity-to-Asset : 0.96 (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ARCA biopharma's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €30.26 Mil. ARCA biopharma's Total Assets for the quarter that ended in Jun. 2024 was €31.44 Mil.

The historical rank and industry rank for ARCA biopharma's Equity-to-Asset or its related term are showing as below:

FRA:HQ10' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83   Med: 0.93   Max: 0.98
Current: 0.96

During the past 13 years, the highest Equity to Asset Ratio of ARCA biopharma was 0.98. The lowest was 0.83. And the median was 0.93.

FRA:HQ10's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs FRA:HQ10: 0.96

ARCA biopharma Equity-to-Asset Historical Data

The historical data trend for ARCA biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Equity-to-Asset Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.92 0.93 0.97 0.98

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.97 0.98 0.96 0.96

Competitive Comparison of ARCA biopharma's Equity-to-Asset

For the Biotechnology subindustry, ARCA biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Equity-to-Asset falls into.


;
;

ARCA biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

ARCA biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=33.947/34.719
=

ARCA biopharma's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=30.26/31.441
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARCA biopharma  (FRA:HQ10) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


ARCA biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines